StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$51.35+0.38 (+0.75%)

Close on Nov 19, 2026

Genmab A/S Development, Regulatory & Commercial Milestone Revenue by Quarter

Development, Regulatory & Commercial Milestone Revenue ($M)

Genmab A/S Development, Regulatory & Commercial Milestone Revenue: $5M in Q3 2026, down 90.6% from a year earlier.

Latest, Q3 2026
5
Period ended Sep 30, 2026
Change on a year earlier
-90.6%
53 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

“|| Milestone revenue | 5 | 53 | 31 | 66”

Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Genmab A/S Development, Regulatory & Commercial Milestone Revenue ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/rev-milestone

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?